Skip to Main Content

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Conditions

Phase I

Phase I

What is the purpose of this trial?

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

  • Trial with
    Mirati Therapeutics
  • Start Date
    08/03/2020
  • End Date
    11/30/2020

For more information about this study, contact:

Nicole Sinclair

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/15/2020
  • Study HIC
    #2000026742